Loading stock data…
$58.37+1.80 (+3.18%)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
Royalty Pharma plc in the Healthcare sector is trading at $58.37 with a market capitalization of $34.1B. Wall Street consensus targets $65.38 (8 analysts), implying a +12.0% move over the next 12 months. The stock is currently 9% below its 52-week high of $64.38, remaining 13.3% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $674.14M↑ | $630.58M↑ | $621.99M↑ | $609.29M↑ | $578.66M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $133.12M↓ | $632.48M↑ | $388.38M↓ | $427.16M↑ | $209.80M |
| Net Income | $17.88M↓ | $294.69M↑ | $214.21M↓ | $288.22M↑ | $32.18M |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-sta...